UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
CAMBRIDGE, Mass., Oct. 03, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it will present at 9:00 a.m. ET and participate in a panel discussion at 10:00 a.m. ET at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016 in New York City.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
